Predicting Aromatase Inhibitor Responsiveness in Endometrial Carcinoma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 43
- 试验地点
- 2
- 主要终点
- Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer
研究概览
简要总结
Some cases of endometrial cancer are dependent on estrogen for their growth. Letrozole blocks estrogen production in the body. The purpose of this study is to determine if the investigators can predict which patients might benefit from Letrozole treatment by studying the many different forms of the estrogen receptor molecule that exist within the cancer tissues. To participate in this study, the patients must be 40 years of age or older and have biopsy-proven endometrial carcinoma, either well differentiated or moderately differentiated forms. Also, to be eligible to participate in this study, the patients need to be healthy enough to have a hysterectomy. If the patients are less than age 60, they will need a blood test (FSH) to confirm that they have gone into menopause.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •FIGO grade 1 or 2 endometrioid adenocarcinoma of the endometrium
- •Post menopausal status must be demonstrated
- •Signed informed consent
排除标准
- •FIGO grade 3 endometrioid adenocarcinoma or non-endometrioid cancers of the endometrium
- •Younger than 40 or postmenopausal status not established
- •Pregnant or breastfeeding
研究组 & 干预措施
Letrozole
letrozole 2.5 mg PO daily for 2-3 weeks prior to hysterectomy.
干预措施: Letrozole (Drug)
结局指标
主要结局
Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer
时间窗: At time of consent and after hysterectomy (generally about 3 weeks)
Changes in %Ki67 staining cells by immunoperoxidase of paraffin embedded, formalin fixed tissue
次要结局
未报告次要终点